Full Press Release Details
Cryoport Revenue Up 52% for the Second
Quarter of 2017, Driven by Biopharma
Biopharma revenue up 69% year-over-year;
33 new clinical trials supported during second quarter
IRVINE, CA - Aug 8, 2017 -
Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry,
today announced financial results for the three and six-month periods ended June 30, 2017.
"As the most advanced solutions provider
of temperature controlled logistics serving the life sciences, Cryoport is setting the "gold standard" for reproductive
medicine, animal health and biopharma, particularly within the dynamic regenerative medicine market as we position our Company
for significant revenue growth for years to come," commented Jerrell Shelton, Cryoport's Chief Executive Officer. "Recently
Novartis selected us to support its impending commercial launch of CAR T-cell therapy, CTL019/CD19,
for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). Our multiyear agreement marks the first commercial
contract in the regenerative medicine market and is a testament to our advanced temperature controlled logistics solutions and
"Commercial agreements such as these",
he continued, "will undoubtedly grow and as we provide our vital services, these types of relationships have the potential
to drive substantial revenue growth for Cryoport. We are a transformative temperature controlled logistics solution provider serving
a transformative biopharma industry, which, we think, has enormous growth ahead of it.
"So, it should be clear that our
sales and marketing strategy is, therefore, largely centered on securing clinical trial logistics solution agreements with biopharma
companies, which position Cryoport to expand its service agreements as therapies move through the clinical trial phases and move
to commercial viability. During the second quarter, we secured an additional 33 new clinical trials with new and existing biopharma
companies bringing the total number of trials supported by Cryoport to 172, compared with 90 this time last year. These trials
are a strong foundation from which we will grow our business. It is a special time as the regenerative medicine industry is experiencing
higher levels of activity, with several treatments approaching potential commercialization. We are in a solid position to scale
our business as we continue to strengthen our reputation in the life sciences as the "go to" for advanced, dependable
temperature controlled logistics solutions.
Mr. Shelton concluded, "Biopharma
revenue now accounts for 76% of our total revenue and is clearly our largest growth market. However, our animal health and reproductive
medicine revenue were both up 21% for the six-month period and continue to provide steady cash flow. We are proud of the achievements
of our people, individually, and our team, collectively, as we continue to demonstrate our ability to successfully leverage the
industry-wide growth in the life sciences and to secure revenue opportunities that build Cryoport and value for its shareholders."
Reproductive Medicine
Overall Financial Results:
Further information on Cryoport's
results are included on the attached unaudited condensed consolidated balance sheets and statements of operations, and a further
explanation of Cryoport's financial performance will be provided in Cryoport's quarterly report on Form 10-Q for the
three and six-month periods ended June 30, 2017, which will be filed with the Securities and Exchange Commission ("SEC")
tomorrow, August 9, 2017. The full report will be available on the SEC Filings section of the Investor Relations section of the Company's
website at www.cryoport.com.
The Company will host a conference call
at 4:30 pm ET on August 8, 2017 to review its financial results and business outlook. Cryoport will provide an update on revenue
from its three main lines of business - Biopharma, Animal Health and Reproductive Medicine. Management will also report on
new client activities and provide a general business outlook.
Participants should dial 1-877-407-9716
(United States) or 1-201-493-6779 (International) and request the "Cryoport call". A live audio webcast of the call
and slide deck will also be available on the Investor Relations section of the Company's website at www.cryoport.com
or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.
An archive of the webcast will be available
approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company's
website at www.cryoport.com for a limited time. To access the replay of the webcast, please follow this link. A dial-in replay
of the call will also be available to those interested until August 15, 2017. To access the replay, dial 1-844-512-2921 (United
States) or 1-412-317-6671 (International) and enter replay pin number: 13667050.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted
global provider of temperature controlled logistics solutions for temperature-sensitive life sciences commodities, serving the
biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories,
pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in
IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary
Cryoport Express Shippers, Cryoportal Logistics Management Platform, leading-edge SmartPak II Condition
Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support,
make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to
For more information, visit www.cryoport.com. Sign up to follow
@cryoport on Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in this news release which are not purely historical,
including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or
predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties
associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow,
market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors,
including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Transition
Report on Form 10-K for the nine months ended December 31, 2016 filed with the SEC. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and
does not undertake to update or revise any forward-looking statements in this press release.
Todd Fromer/Elizabeth Barker
Cryoport Inc. and Subsidiary
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues | $ | 2,917,378 | $ | 1,917,566 | $ | 5,629,612 | $ | 3,473,111 | ||||||||
| Cost of revenues | 1,524,189 | 1,135,616 | 2,982,926 | 2,109,354 | ||||||||||||
| Gross margin | 1,393,189 | 781,950 | 2,646,686 | 1,363,757 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| General and administrative | 1,789,514 | 1,429,768 | 3,492,546 | 3,244,189 | ||||||||||||
| Sales and marketing | 1,236,833 | 1,195,638 | 2,306,768 | 2,442,664 | ||||||||||||
| Research and development | 230,736 | 135,799 | 480,579 | 280,277 | ||||||||||||
| Total operating costs and expenses | 3,257,083 | 2,761,205 | 6,279,893 | 5,967,130 | ||||||||||||
| Loss from operations | (1,863,894 | ) | (1,979,255 | ) | (3,633,207 | ) | (4,603,373 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (26 | ) | (21,242 | ) | (15,693 | ) | (102,436 | ) | ||||||||
| Warrant repricing expense | - | (1,929,818 | ) | - | (1,929,818 | ) | ||||||||||
| Other income (expense), net | 3,463 | (1,915 | ) | 3,463 | (6,787 | ) | ||||||||||
| Loss before provision for income taxes | (1,860,457 | ) | (3,932,230 | ) | (3,645,437 | ) | (6,642,414 | ) | ||||||||
| Provision for income taxes | - | (2,484 | ) | (4,231 | ) | (2,484 | ) | |||||||||
| Net loss | (1,860,457 | ) | (3,934,714 | ) | (3,649,668 | ) | (6,644,898 | ) | ||||||||
| Undeclared cumulative preferred dividends | - | - | - | (75,460 | ) | |||||||||||
| Net loss attributable to common stockholders | $ | (1,860,457 | ) | $ | (3,934,714 | ) | $ | (3,649,668 | ) | $ | (6,720,358 | ) | ||||
| Net loss per share attributable to common stockholders - basic and diluted | $ | (0.08 | ) | $ | (0.28 | ) | $ | (0.18 | ) | $ | (0.54 | ) | ||||
| Weighted average shares outstanding - basic and diluted | 23,965,825 | 14,199,742 | 20,802,628 | 12,428,991 |
Cryoport Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| June 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| (unaudited) | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 12,854,526 | $ | 4,524,529 | ||||
| Accounts receivable, net | 1,250,731 | 1,195,479 | ||||||
| Inventories | 72,621 | 89,499 | ||||||
| Prepaid expenses and other current assets | 308,929 | 286,919 | ||||||
| Total current assets | 14,486,807 | 6,096,426 | ||||||
| Property and equipment, net | 2,311,680 | 1,647,104 | ||||||
| Intangible assets, net | 29,728 | 5,000 | ||||||
| Deposits | 363,403 | 363,403 | ||||||
| Total assets | $ | 17,191,618 | $ | 8,111,933 | ||||
| Current liabilities: | ||||||||
| Accounts payable and other accrued expenses | $ | 1,369,223 | $ | 1,160,299 | ||||
| Accrued compensation and related expenses | 598,325 | 419,034 | ||||||
| Related party notes payable and accrued interest, net of discount | - | 651,934 | ||||||
| Total current liabilities | 1,967,548 | 2,231,267 | ||||||
| Deferred rent liability | 196,973 | 200,264 | ||||||
| Total liabilities | 2,164,521 | 2,431,531 | ||||||
| Total stockholders' equity | 15,027,097 | 5,680,402 | ||||||
| Total liabilities and stockholders' equity | $ | 17,191,618 | $ | 8,111,933 |
Note Regarding Use of Non-GAAP Financial
This news release contains non-GAAP financial measures as
defined in Regulation G of the Securities Exchange Act of 1934. These financial measures are not calculated in accordance with
generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles. In
evaluating the Company's performance, management uses certain non-GAAP financial measures to supplement financial statements prepared
under GAAP. Management believes the following non-GAAP financial measure, adjusted EBITDA, to provide a useful measure of the Company's
operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the
Company's ongoing operating performance. Further, management and the Board of Directors utilize these non-GAAP financial measures
to gain a better understanding of the Company's comparative operating performance from period-to-period and as a basis for planning
and forecasting future periods. Management believes these non-GAAP financial measures, when read in conjunction with the Company's
GAAP financials, are useful to investors because they provide a basis for meaningful period-to-period comparisons of the Company's
ongoing operating results, including results of operations, against investor and analyst financial models, identifying trends in
the Company's underlying business and performing related trend analyses, and they provide a better understanding of how management
plans and measures the Company's underlying business.